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Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor for responses to low oxygen. Different nonhypoxic stimuli,
including hormones and growth factors, are also important HIF-1 activators in the vasculature. Angiotensin II (Ang II), the
main effecter hormone in the renin-angiotensin system, is a potent HIF-1 activator in vascular smooth muscle cells
(VSMCs). HIF-1 activation by Ang II involves intricate mechanisms of HIF-1 transcription, translation, and protein
stabilization. Additionally, the generation of reactive oxygen species (ROS) is essential for HIF-1 activation during Ang
II treatment. However, the role of the different VSMC ROS generators in HIF-1 activation by Ang II remains unclear. This
work aims at elucidating this question. Surprisingly, repression of NADPH oxidase-generated ROS, using Vas2870, a
specific inhibitor or a p22phox siRNA had no significant effect on HIF-1 accumulation by Ang II. In contrast, repression of
mitochondrial-generated ROS, by complex III inhibition, by Rieske Fe-S protein siRNA, or by the mitochondrial-targeted
antioxidant SkQ1, strikingly blocked HIF-1 accumulation. Furthermore, inhibition of mitochondrial-generated ROS
abolished HIF-1 protein stability, HIF-1–dependent transcription and VSMC migration by Ang II. A large number of
studies implicate NADPH oxidase–generated ROS in Ang II–mediated signaling pathways in VSMCs. However, our
work points to mitochondrial-generated ROS as essential intermediates for HIF-1 activation in nonhypoxic conditions.
INTRODUCTION
Hypoxia-inducible factor-1 (HIF-1) is a key hypoxia-induc-
ible transcription factor responsible for the adaptation of
cells and tissues to low oxygen by regulating such responses
as cell metabolism, proliferation and survival, erythropoie-
sis, and angiogenesis (Semenza, 2003). HIF-1 binds to hy-
poxia-response elements (HRE) found in promoter or en-
hancer DNA regions of target hypoxia-inducible genes that
include vascular endothelial growth factor (VEGF), glucose
transporter-1 (Glut-1), nitric oxide synthases, and likely be-
tween 100 and 200 others (Kaelin and Ratcliffe, 2008).
The active HIF-1 complex is a heterodimer consisting of
an oxygen-sensitive HIF-1 subunit and a constitutively
expressed HIF-1 subunit. HIF-1 possesses an oxygen-de-
pendent degradation domain (ODDD) containing two key
proline residues which are, in the presence of oxygen, hy-
droxylated by HIF prolyl-hydroxylases (PHDs; Kaelin and
Ratcliffe, 2008). HIF-1 prolyl-hydroxylation allows for rec-
ognition by pVHL, the product of the von Hippel-Lindau
tumor suppressor gene, the substrate recognition compo-
nent of an E3 ubiquitin ligase complex that polyubiquiti-
nates and targets HIF-1 for proteasomal degradation. In
hypoxic conditions, low oxygen leads to HIF-1 stabilization
due to inhibition of prolyl-hydroxylation and subsequent
decreases in HIF-1 ubiquitination and degradation (Cock-
man et al., 2000; Epstein et al., 2001; Schofield and Ratcliffe,
2004).
In addition to hypoxia, there are also different nonhypoxic
HIF activators that include growth factors, hormones, cyto-
kines, and viral proteins (Dery et al., 2005). In vascular
smooth muscle cells (VSMCs) we have shown that angioten-
sin II (Ang II), a vasoactive hormone linked to many cardio-
vascular functions and diseases, is a potent HIF-1 activator
(Richard et al., 2000). Treatment of VSMCs with Ang II
regulates HIF-1 by common as well as distinct mechanisms
from hypoxia. Ang II increases HIF-1 stability (as in hyp-
oxia), but additionally increases HIF-1 translation and tran-
scription (Page et al., 2002, 2008; Lauzier et al., 2007).
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Reactive oxygen species (ROS) are small, extremely reac-
tive molecules due to their unpaired valence electrons. High
ROS concentrations are very damaging to cells, because they
lead to a free-radical–mediated chain reaction–targeting pro-
teins, lipids, polysaccharides, and DNA (Turrens, 2003).
However, low and intermediary levels of ROS are crucial to
a number of cellular signaling events (Cai et al., 2002; Varela
et al., 2004; Felty et al., 2005; Kimura et al., 2005b; Rhee, 2006;
Zhang et al., 2007; Lassegue and Griendling, 2010). There are
a number of intracellular ROS generators. Two of the most
documented include the NADPH (reduced nicotinamide
adenine dinucleotide phosphate) oxidase and the mitochon-
dria. The NADPH oxidase is a complex comprised of
membrane bound (Nox1-4 and p22phox) and cytoplasmic
(p47phox, p67phox and Rac) subunits (Babior, 2004). Once
activated, cytoplasmic subunits interact with their mem-
brane-bound counterparts and create an active complex
which oxidizes NADPH, leading to the generation of ROS.
In VSMCs, a large body of literature indicates that NADPH
oxidase–derived ROS (noxROS) are a primary source of
ROS after Ang II treatment (Sorescu et al., 2001; Garrido and
Griendling, 2009). On the other hand, mitochondria mainly
produce ROS at complex I and complex III of the electron
transport chain, whereas a total of nine other ROS-produc-
ing sites have been identified (Andreyev et al., 2005). Inter-
estingly, complex III produces ROS in both the mitochon-
drial matrix and the intermembrane space, whereas the
other sites produce superoxide solely in the mitochondrial
matrix (Zhang et al., 2007). Mitochondrial-derived ROS
(mtROS) have recently gained attention in vascular biology
and were shown to be increased by Ang II (Kimura et al.,
2005a; Doughan et al., 2008; Nozoe et al., 2008).
Our studies have shown that the generation of ROS dur-
ing Ang II treatment is essential for both increased HIF-1
translation and stability. Ang II augments HIF-1 translation
by noxROS-dependent increases in receptor tyrosine kinase
transactivation and phosphatidylinositol 3-kinase (PI3K)/
p70S6 kinase (p70S6K) pathway activation (Page et al., 2002;
Lauzier et al., 2007). Additionally, our recent work indicated
that ROS/H2O2 increased HIF-1 protein accumulation
through a Fenton reaction where Fe2, an essential PHD
cofactor, is oxidized to Fe3, leading to the inactivation of
PHD, decreased HIF-1 hydroxylation, and increased
HIF-1 protein stabilization (Page et al., 2008).
Here, we set out to identify the ROS generator responsible
for HIF-1 stabilization during Ang II treatment. Surpris-
ingly, we show that targeting noxROS generation did not
play a major role in HIF-1 stabilization and accumulation
in VSMCs treated with Ang II. Instead, the specific targeting
of mtROS generation by inhibition of mitochondrial com-
plex III and by using mitochondrial-targeted antioxidants
completely abolishes HIF-1 stabilization and accumulation
during the treatment of VSMCs with Ang II by reestablish-
ing PHD activity and HIF-1 hydroxylation. Additionally,
Ang II–stimulated HIF-1 activity in VSMCs, measured by
HIF-1–mediated target gene expression and VSMC migra-
tion depends on mtROS generation. These results indicate
that mtROS are essential intermediates for HIF-1 induction
and activation by Ang II in VSMCs.
MATERIALS AND METHODS
Materials
Ang II, PDGF-BB, myxothiazol, and stigmatellin were all from Sigma-Aldrich
(St. Louis, MO). MG132 was from EMD Chemicals (Gibbstown, NJ). VAS2870
was from Vasopharm (Wuerzburg, Germany). Anti-HIF-1 antibody was
raised in our laboratory in rabbits immunized against the last 20 amino acids
of the C terminal of human HIF-1 (Richard et al., 1999). Anti-hydroxylated
HIF-1 antibodies, against either hydroxylated Pro402 or hydroxylated Pro564
of human HIF-1, were obtained as previously described (Chan et al., 2002,
2005). Monoclonal anti-phospho-p42/p44 MAPK and anti--tubulin antibod-
ies were from Sigma-Aldrich. Anti-phospho-p70S6 kinase (Thr389), p70S6
kinase, phospho-AKT, AKT, and monoclonal p38 MAP kinase antibodies
were from Cell Signaling (Beverly, MA). p22phox and Rieske Fe-S protein
monoclonal antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-phospho-p38 (pTpY180/182) polyclonal antibody was from Invitro-
gen (Carlsbad, CA). Total polyclonal p42/p44 MAPK antibody was from
Upstate/Millipore (Billerica, MA). Anti-glutathione S-transferase (GST) anti-
body was from Novus Biologicals (Littleton, CO). Monoclonal HA.11 anti-
body was from Covance (Emeryville, CA). Horseradish peroxidase-coupled
anti-mouse and anti-rabbit antibodies were from Promega (Madison, WI). A
GST-HIF-1 fusion protein, comprised of amino acids 344-582 from human
HIF-1, and pVHL-hemagglutinin (HA) constructs were kind gifts from Drs.
Jacques Pouysse´gur and Peter Ratcliffe respectively. The mitochondrial anti-
oxidant, SkQ1 was from Drs. Vladimir Skulachev and Oleg Fedorkin at the
Institute of Mitoengineering, Moscow State University (Skulachev et al., 2009).
Cell Culture
Rat VSMCs were isolated from the thoracic aortas of 6 wk-old male Wistar
rats by enzymatic dissociation (Owens et al., 1986). Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 50 U/ml penicillin, 50 U/ml streptomycin (Invitrogen,
Carlsbad, CA) and 2 mM glutamine in a humid atmosphere (5% CO2, 95%
air). Cells were serially passaged once reaching confluence, and only cells
between passages 4 and 12 were used for experiments. In all experiments,
cells were deprived of serum overnight. For MitoSOX assays, cells were
cultured in phenol red–free DMEM. Hypoxic conditions were obtained by
placing cells in a sealed hypoxic workstation (Ruskinn Technology, Bridgend,
United Kingdom). The oxygen level in this workstation was maintained at
1%, with the residual gas mixture containing 94% nitrogen and 5% CO2.
Western Blot Analysis
Confluent cells were lysed in a 2 Laemmli buffer. Protein concentration was
determined by Lowry assay. Samples were resolved on SDS-polyacrylamide
gels and electrophoretically transferred to polyvinylidene difluoride mem-
branes (PVDF, Immobilon-P, Millipore). Proteins were analyzed using indi-
cated antibodies and visualized with an enhanced chemiluminescence (ECL)
system (GE Healthcare, Piscataway, NJ) or with the Odyssey Infrared Imag-
ing System (LI-COR Biosciences, Lincoln, NE). Western blots were quantified
using Odyssey quantification software (LI-COR Biosciences) or ImageJ (Na-
tional Institutes of Health; http://rsb.info.nih.gov/ij/).
RNA Silencing
Cells were seeded in six-well plates at a density of 6  105 cells/well. Twenty-
four hours after plating, small interfering RNA (siRNA) oligonucleotides were
transfected by CaPO4 precipitation. Thirty-six hours after transfection, cells were
then deprived of FBS for 16 h before stimulation. All siRNAs were obtained from
Applied Biosystems/Invitrogen and the specific sequences used are as follows:
rat HIF-1 (accession no. NM_024359): sense: 5-AGGACAAGUCACCACAG-
GAuu-3; rat p22phox (accession no. NM_024160): sense: 5-AAGUACCUGAC-
CGCUGUGGtg-3; rat Rieske Fe-S (accession no. NM_001008888; predesigned
siRNA (accession no. s145479): sense 5-GCAUGAUUUAGAGCGUGUAtt-3. As
a control oligonucleotide, Silencer Negative Control 2 siRNA was used.
mtROS Assay
mtROS production was determined using MitoSOX Red mitochondrial su-
peroxide indicator (Invitrogen), which is selectively targeted to the mitochon-
dria and is fluorescent upon ROS oxidation. MitoSOX was used according to
the manufacturer’s protocol and published literature (Robinson et al., 2008).
Briefly, VSMCs were seeded on glass-bottomed cell culture dishes and serum-
deprived overnight in phenol red-free DMEM. VSMCs were then incubated
with MitoSOX (1 M) for a total of 1 h before analysis. Cells were then
pretreated or not with inhibitors as indicated 20 min after MitoSOX addition.
Ang II (100 nM) was added during the final 20 min. Cell imaging was
performed with a FV1000 confocal microscope equipped with a live cell
apparatus (60 oil, 1.4 NA) driven by FluoView software (Olympus, Tokyo,
Japan). Fluorescence quantification was performed using the Measure Inte-
grated Density function of the ImageJ software.
HIF-1 Half-Life Analysis
VSMCs were pretreated with stigmatellin or myxothiazol for 20 min and then
treated with Ang II. After 4 h, cycloheximide (30 g/ml) was added for
different periods of time (up to 30 min). VSMCs were then lysed in a 2
Laemmli buffer. HIF-1 and -tubulin protein levels were evaluated by
Western blotting followed by quantification and the ratio of HIF-1 to -tu-
bulin was determined. HIF-1 half-life under experimental conditions was
estimated by plotting data as the HIF-1–-tubulin ratio versus time under
cycloheximide treatment.
D. A. Patten et al.
Molecular Biology of the Cell3248
pVHL Capture Assay
pVHL capture assay was performed as previously described (Page et al.,
2008). Briefly, VSMCs were grown to confluence, serum-deprived for 16 h,
and stimulated as indicated for 4 h. Cells were washed once in PBS and twice
in ice-cold HEB buffer (20 mM Tris, pH 7.5, 5 mM KCl, 1.5 mM MgCl2, 1 mM
dithiothreitol). Cells were then lysed using a Dounce homogenizer, and
cytoplasmic extracts were isolated by centrifugation (20,000 g). Cytoplasmic
extracts (250 g) were incubated with Sepharose-bound GST-HIF-1 (30 g)
for 1 h at room temperature. The Sepharose-bound GST-HIF-1 was then
washed with NETN buffer (150 mM NaCl, 0.5 mM EDTA, 20 mM Tris, pH 8.0,
0.5% Igepal, 100 M deferoxamine) and incubated overnight with in vitro–
translated pVHL-HA in NETN at 4°C. Samples were then washed with
NETN, denatured with 2 Laemmli buffer, resolved in SDS-polyacrylamide
gels (12%), and revealed using anti-HA and anti-GST antibodies.
Intracellular Ascorbate Assay
VSMCs were grown to confluence on 100-mm plates in culture media sup-
plemented with ascorbate (250 M). Cells were serum-deprived for 16 h in
ascorbate supplemented DMEM, and fresh DMEM without ascorbate was
added 1 h before treatments. Cells were washed with PBS and lysed in a 90%
methanol/1 mM EDTA solution. Samples were briefly sonicated and centri-
fuged at 20,000  g. Ascorbate levels were then analyzed by spectrophotom-
etry using a modified protocol (Queval and Noctor, 2007). Samples were
diluted in 0.2 mM NaH2PO4, pH 5.6, and absorbance was measured at 265
nm. Ascorbate peroxidase (0.4 U) was added to samples for 5 min, and the
absorbance was again measured at 265 nm. Ascorbate concentrations were
determined as the difference in absorbance prior and after the addition of
ascorbate peroxidase. A Lowry protein assay was used for normalization of
the samples.
Northern Blot Analysis
Confluent VSMCs were lysed with TRIzol reagent (Invitrogen). RNA and
protein were extracted according to the manufacturer’s protocol. RNA con-
centration was then quantified using RiboGreen (Invitrogen). RNA (20 g)
was resolved on 1% agarose/6% formaldehyde gels and transferred to Hy-
bond N nylon membranes (GE Healthcare) before hybridization with a
radioactive cDNA probes comprising either the total coding sequence of the
mouse VEGF gene and the human GLUT1 gene or the 900-base pair coding
sequence of the human HIF-1 gene. An oligonucleotide probe against 18S
rRNA was used as a loading control. Northern blots were quantified using a
STORM phosphoimaging system equipped with ImageQuant software (GE
Healthcare Life Sciences).
Cell Migration Assay
VSMCs were serum deprived for 16 h before determination of cell migration
by Boyden chamber assay using a 48-well reusable chamber (Neuroprobe,
Gaithersburg, MD). Polycarbonate PVPF membranes (8.0 m; GE Water &
Process Technologies, Trevose, PA), coated with rat tail type I collagen (VWR
International, West Chester, PA), were used to separate the upper and lower
chambers. VSMCs were added to the upper chamber at a density of 5  104
cells per well in DMEM containing 0.1% fatty-acid-free BSA. VSMCs were
allowed to migrate toward the lower chamber containing media with or
without 100 nM Ang II and inhibitors for 4 h at 37°C. After treatment,
membranes were fixed with methanol and subjected to Giemsa staining
(Thermo Fisher Scientific, Waltham, MA). Removal of nonmigrated cells was
performed by wiping membranes with cotton swabs. Membranes were then
air dried on a microscope slide. Cells were counted in three different fields.
Results shown are means  SD of four independent experiments performed
in triplicate.
Statistical Analysis
For Western blot and imaging studies, results are representative of three
independent experiments. Unless otherwise noted, quantification results are
expressed as means  SEM of three independent experiments. Statistical
analyses of different experiments were performed using InStat 3 (GraphPad).
Unless otherwise noted, Student’s t tests were performed. Results were
deemed significant if they attained a 95% confidence level (p  0.05).
RESULTS
noxROS Do Not Play a Major Role in HIF-1
Accumulation by Ang II in VSMCs
A large body of evidence indicates that the NADPH oxidase
is the principle ROS generator in Ang II–treated VSMCs
(Lyle and Griendling, 2006; Garrido and Griendling, 2009).
We therefore decided to first examine whether NADPH
oxidase– derived ROS were implicated in HIF-1 accumu-
lation under nonhypoxic conditions. VAS2870, a specific
NADPH oxidase inhibitor, was first used to inhibit noxROS
generation (ten Freyhaus et al., 2006). As seen in Figure 1A,
when used at reported functional concentrations (10–50
M), VAS2870 showed no effect on increased HIF-1 protein
levels in VSMCs treated with Ang II. We also investigated
the role of noxROS using a molecular approach. Inhibiting
the p22phox subunit can abolish noxROS generation because
this membrane bound protein is an essential member of the
NADPH oxidase complex (Ushio-Fukai et al., 1996; Ambasta
et al., 2004; Hanna et al., 2004; Modlinger et al., 2006). Tar-
geting the p22phox subunit with a specific siRNA was able to
efficiently decrease p22phox protein levels in VSMCs (Figure
1B). However, p22phox silencing was unable to modify
HIF-1 protein levels after a treatment with Ang II. Activa-
tion of the PI3K pathway has been linked to NADPH oxi-
dase activity and noxROS generation (Page et al., 2002;
Baumer et al., 2008). We therefore determined if NADPH
oxidase inhibition with VAS2870 or p22phox siRNA inhibited
the PI3K pathway by evaluating p70S6 kinase (p70S6K)
phosphorylation, a downstream target of this pathway. As
seen in Figure 1, A and B, Ang II–induced p70S6K phos-
phorylation was indeed inhibited by pretreatment of VSMCs
with both VAS2870 and p22phox siRNA. These results indi-
cate that noxROS generation does not play a major role in
regulating HIF-1 accumulation in VSMCs during Ang II
stimulation.
Figure 1. noxROS do not regulate HIF-1 accumulation. (A) Qui-
escent VSMCs were pretreated with VAS2870 (indicated concentra-
tions) for 20 min and then treated or not with Ang II (100 nM) for
4 h. HIF-1, phospho-p70S6K, total-p70S6K, and -tubulin levels
were then analyzed by Western blot. (B) VSMCs were transfected
with a siRNA against p22phox or a control sequence. Quiescent
VSMCs were treated or not with Ang II (100 nM) for 4 h. HIF-1,
p22phox, phospho-p70S6K, total-p70S6K, and -tubulin levels were
then analyzed by Western blot.
Ang II, mtROS, and HIF-1
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mtROS Are Essential for Increased HIF-1 Accumulation
by Ang II in VSMCs
We next attempted to determine the role of mitochondrial-
generated ROS in HIF-1 accumulation by Ang II. We first
used a pharmacological approach, using stigmatellin and
myxothiazol, two inhibitors of the mitochondrial electron
transport chain (ETC), specifically complex III. Interestingly,
both compounds strikingly inhibited HIF-1 accumulation
by Ang II (Figure 2A). However, myxothiazol and stig-
matellin were unable to inhibit HIF-1 accumulation by
CoCl2 (Supplemental Figure 1), a HIF-1 inducer that po-
tently inhibits HIF-1 hydroxylation and functions indepen-
dently of oxygen levels and mtROS generation (Sanjuan-Pla
et al., 2005). Using MitoSOX, a mitochondrial-targeted probe
for detecting ROS, results show that treatment of VSMCs
with Ang II does indeed increase mtROS generation (Figure
2B). As expected, stigmatellin and myxothiazol both inhib-
ited mtROS generation in VSMCs by Ang II (Figure 2B),
whereas VAS2870 was ineffective (Supplemental Figure 2A).
Our previous studies have shown that diphenyleneiodonium
(DPI), which blocks ROS generation through its activity as a
flavoprotein-containing enzyme inhibitor, potently represses
Ang II–induced HIF-1 accumulation in VSMCs (Richard et al.,
2000; Page et al., 2002). In accordance with our past studies, DPI
also strikingly decreased mtROS generation (Supplemental
Figure 2B). Finally, our results show that pretreatment of
VSMCs with stigmatellin or myxothiazol does not affect other
Ang II/AT1-related cellular signaling because p70S6K,
p38MAPK, AKT, and p42/44 MAPK activation/phosphoryla-
tion levels were not modified (Supplemental Figure 3).
Two additional approaches were used to confirm the role
played by mtROS in HIF-1 induction in VSMCs after Ang II
treatment. First, we investigated the importance of the Rieske
Fe-S protein, an essential member of complex III. Without
Rieske Fe-S, mtROS are not generated because complex III
cannot initiate the Q cycle (Brunelle et al., 2005). As seen with
complex III inhibitors, targeting Rieske Fe-S with a specific
siRNA led to an inhibition of HIF-1 accumulation after Ang II
treatment (Figure 3A). Second, we utilized a mitochondrial-
targeted antioxidant: SkQ1. Developed to investigate the role of
mitochondrial ROS in ageing, this Skulachev (Sk) ion is strongly
localized to the mitochondria. SkQ1 is a “rechargeable” antioxi-
dant because it is reduced by the mitochondrial ETC (Skulachev et
al., 2009). As seen in Figure 4A, the pretreatment of VSMCs with
SkQ1 before Ang II treatment blocked HIF-1 protein accumula-
tion. As expected, both the siRNA knockdown of Rieske Fe-S
and the pretreatment of VSMCs with SkQ1 abolished mtROS
generation by Ang II as determined by MitoSOX staining (Fig-
ures 3B and 4B and Supplemental Figure 4). Taken together,
our results show that in VSMCs, mtROS generation is essential
for Ang II–induced HIF-1 accumulation.
mtROS Are Involved in Increasing HIF-1 Stabilization
Our previous work demonstrated that ROS were essential in
HIF stabilization during the treatment of VSMCs with Ang
II (Page et al., 2008). We therefore attempted to determine the
importance of mtROS on HIF-1 stabilization. We first ex-
amined the role of mtROS on HIF-1 half-life using the
general protein synthesis inhibitor, cycloheximide (Laugh-
ner et al., 2001; Page et al., 2008; Michaud et al., 2009).
Incubating cells with cycloheximide after HIF-1 induction
blocks de novo protein synthesis. Thus, cellular HIF-1 pro-
tein levels are dependent on the maintenance of protein
stabilization mechanisms. In these experimental conditions,
changes in HIF-1 half-life would therefore reflect changes
in HIF-1 stability. Here, HIF-1 half-life was determined by
Western blotting and the quantification of HIF-1 levels
over time in the presence of cycloheximide. When VSMCs
were treated with Ang II, HIF-1 half-life was 20  2.8 min
(Figure 5). However, when VSMCs were pretreated with
either stigmatellin or myxothiazol, HIF-1 half-life under
Ang II treatment was significantly decreased (7.0  0.5 and
5.5  0.6 min, respectively). It is important to note that the
inhibition of mtROS generation did not modify increased
HIF-1 mRNA levels by Ang II (Supplemental Figure 5).
This last result was expected because our studies have
shown that Ang II–increased HIF-1 mRNA levels are ROS-
independent in VSMCs (Page et al., 2002). Therefore, our
results indicate that HIF-1 stability is increased through
Ang II–dependent mtROS generation in VMSC.
We then investigated whether mtROS could act on two
main steps involved in HIF-1 protein degradation; HIF-1
prolyl hydroxylation and HIF-1 binding to pVHL. To an-
alyze HIF-1 hydroxylation status, specific antibodies
against hydroxylated HIF-1 on its two key ODDD proline
residues were used (Chan et al., 2002; Chan et al., 2005). As
seen in Figure 6, VSMCs treated with Ang II show decreased
HIF-1 hydroxylation, most notably on the Pro402 residue
(Page et al., 2008). More interestingly, the decrease in HIF-1
hydroxylation by Ang II was reversed when VSMCs were
Figure 2. mtROS regulate HIF-1 accumulation. (A) Quiescent
VSMCs were pretreated with stigmatellin (Stig, 1 M) or myxothiazol
(Myx, 1 M) for 20 min and then treated or not with Ang II (100 nM)
for 4 h. HIF-1 and -tubulin levels were analyzed by Western blot. (B)
VSMCs were seeded on 35-mm glass-bottomed cell culture dishes and
loaded with MitoSOX (1 M) for 1 h. During the final 40 min, cells
were pretreated or not with stigmatellin (1M) or myxothiazol (1M).
Ang II (100 nM) was then added 20 min before imaging as described in
Materials and Methods. Differential interference contrast microscopy
(DIC) was used for whole cell imaging. Scale bars, 10m. Bottom panel
is the quantification of results from B. Data are expressed as arbitrary
units of MitoSOX fluorescence and are an average  SD of five inde-
pendent experiments, n  50 cells. ***p  0.001 compared with un-
treated VSMCs. †††p  0.001 compared with Ang II–treated VSMCs.
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pretreated with either stigmatellin or myxothiazol. Addi-
tionally, VAS2870 had no significant effect on HIF-1’s hy-
droxylation status during Ang II treatment. A crucial event
leading to HIF-1 protein degradation is its binding to the
product of the von Hippel-Lindau tumor suppressor gene,
pVHL. Binding to pVHL is a direct result of HIF-1 hydroxy-
lation (Ivan et al., 2001). To determine the effect of Ang II–
induced mtROS generation on pVHL binding, a pVHL capture
assay was used. A GST-HIF-1 fusion protein, comprised of
amino acids 344-582 from human HIF-1, was subjected to
modification by Ang II–treated VSMCs cell extracts followed
by interaction with in vitro–translated pVHL. As we previ-
ously demonstrated, Ang II treatment led to decreased HIF-1
binding to pVHL (Figure 7). More interestingly, pretreatment
of VSMC with stigmatellin or myxothiazol was able to restore
HIF-1 binding to pVHL (Figure 7A). Finally, VAS2870 or
siRNA against p22phox had no significant effect on HIF-1’s
hydroxylation status or levels of pVHL binding during Ang II
treatment (Figures 6 and 7). It is important to note that inhib-
itors or p22phox had no significant effect on HIF-1 hydroxyla-
tion or pVHL binding in cells not treated with Ang II (data not
shown). Taken together, these results indicate that Ang II–
generated mtROS are essential for HIF-1 prolyl-hydroxylase
inactivation in VSMCs.
Our previous studies showed that HIF-1 prolyl hydrox-
ylase activity is inactivated during Ang II stimulation by a
ROS-induced depletion of intracellular ascorbate (Page et al.,
2008). To determine whether mtROS were implicated in de-
Figure 3. mtROS regulate HIF-1 accumulation. (A) VSMCs were
transfected with a siRNA against Rieske Fe-S protein (100 nM) or a
control sequence. Cells were then serum-deprived overnight and
treated or not with Ang II (100 nM) for 4 h. HIF-1, Rieske Fe-S
protein, and -tubulin levels were analyzed by Western blot. (B)
VSMCs seeded on glass-bottomed cell culture dishes were trans-
fected and treated as in A. Cellular mtROS levels were analyzed by
MitoSOX staining as described in Figure 2. Scale bars, 10 m.
Figure 4. mtROS regulate HIF-1 accumulation. (A) Quiescent
VSMCs were pretreated with SkQ1 (500 nM) and then treated or not
with Ang II (100 nM) for 4 h. HIF-1, phospho p42/p44 MAPK, total
p42/p44 MAPK and -tubulin levels were analyzed by Western blot.
(B) VSMCs seeded on glass-bottomed cell culture dishes were trans-
fected and treated as in A. Cellular mtROS levels were analyzed by
MitoSOX staining as described in Figure 2. Scale bars, 10 m.
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pleting intracellular ascorbate, ascorbate levels were measured
in Ang II–stimulated VSMCs that were pretreated with stig-
matellin or myxothiazol. As seen in Supplemental Figure 6,
Ang II treatment decreased intracellular ascorbate levels by
65.2  6.2%. The inhibition of mtROS generation with stig-
matellin or myxothiazol was able to completely reverse intra-
cellular ascorbate depletion caused by the treatment of VSMCs
with Ang II. These results indicate that mtROS generation by
Ang II in VSMCs leads to reduced cellular ascorbate concen-
trations, decreased HIF-1 hydroxylation, decreased HIF-1
binding to pVHL and increased HIF-1 stability.
mtROS Are Required for Increased HIF-1 Transcriptional
Activity by Ang II
The importance of mtROS for HIF-1 transcriptional activity
was analyzed by evaluating the expression of two HIF-1 target
genes: VEGF and Glut-1. As seen in Figure 8, Ang II increased
the expression of both VEGF and Glut-1, an effect that was
strongly inhibited by pretreating cells with either stigmatellin
or myxothiazol. As with HIF-1 protein accumulation, a max-
imal inhibition was observed with 1 M of either complex III
inhibitor (Supplemental Figure 7). To confirm that VEGF and
Glut-1 expression during Ang II treatment were indeed depen-
dent on HIF-1 in VSMCs, we targeted HIF-1 expression with
a specific siRNA. Our results show that the expression of these
two transcripts is nearly exclusively dependent on HIF-1 acti-
vation (Supplemental Figure 8A). Effective silencing of HIF-1
can be observed in Supplemental Figure 8B. Taken together,
these results indicate that Ang II regulates HIF-1–dependent
genes such as VEGF and Glut-1 through mtROS generation in
VSMCs.
HIF-1 and mtROS Are Essential for Ang II–induced VSMC
Migration
VSMC migration occurs during a number of different vascular
pathologies, especially when vascular remodeling is involved
(Gerthoffer, 2007). Ang II is a potent vascular remodeler and
activator of VSMC migration (Xi et al., 1999; Guo et al., 2009).
Additionally, HIF-1 was shown to be important for VSMC
migration in hypoxic conditions (Corley et al., 2005; Osada-Oka
et al., 2008). We wanted to determine whether HIF-1 and
mtROS were involved in Ang II–mediated VSMC migration.
For this assay, we used a Boyden chamber to analyze the
potential of VSMCs to migrate across a porous membrane
Figure 5. mtROS regulate HIF-1 half-life. (A) Quiescent VSMCs
were pretreated with stigmatellin (1 M) or myxothiazol (1 M) for
20 min and then treated or not with Ang II (100 nM) for 4 h. HIF-1
half-life was measured by then treating cells with cycloheximide (30
g/ml) for the indicated times to block all de novo protein synthe-
sis. HIF-1 and -tubulin levels were then analyzed by Western
blot. (B) HIF-1 protein levels in A were quantified using the
Odyssey Infrared Imaging System and normalized to -tubulin.
HIF-1 half-life was determined by plotting data as HIF-1–-
tubulin ratio versus time under cycloheximide treatment. Data ex-
pressed are an average  SEM of three independent experiments.
**p  0.01 compared with Ang II–treated VSMCs.
Figure 6. mtROS regulate HIF-1 hydroxylation. Quiescent VSMCs
were pretreated with stigmatellin (1 M), myxothiazol (1 M), or
VAS2870 (10 M) for 20 min. Cells were then treated with MG132 (20
M) to increase HIF-1 levels and stimulated with Ang II (100 nM) or
CoCl2 (200 M) for 4 h. Nuclear extracts (100 g) were analyzed by
Western blot with anti-hydroxylated-Pro402-HIF-1 (P402-OH), anti-
hydroxylated-Pro564-HIF-1 (P564-OH), anti-HIF-1 and anti--tubu-
lin antibodies (top). Western blots in A were quantified with ImageJ or
the Odyssey Infrared Imaging System using -tubulin as a loading
control (bottom panel). Results are expressed as a percentage of hy-
droxylated HIF-1 (normalized to total HIF-1 protein levels) on Pro402
(f) or Pro564 (u) compared with untreated cells and are an average 
SEM of three independent experiments. **p  0.01 and *p  0.05
compared with untreated VSMCs.
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toward Ang II. HIF-1’s role in VSMC migration was deter-
mined by targeting HIF-1 expression with a specific siRNA
(Supplemental Figure 8). As seen in the top panel of Figure 9,
Ang II significantly increased the migration of VSMCs trans-
fected with a control siRNA that was nearly completely
blocked in VSMCs transfected with a HIF-1 siRNA. To
determine the role of mtROS in Ang II–mediated VSMC
migration, VSMCs were treated with stigmatellin and
myxothiazol during Boyden chamber assay. Both com-
pounds potently inhibited VSMC migration toward Ang
II (Figure 9, bottom panel). Interestingly, the effects of
HIF-1 and mtROS on VSMC migration were specific to
Ang II because VSMC migration toward PDGF-BB was
unaffected by HIF-1 knockdown or complex III inhibi-
tion. Taken together, our results demonstrate the essential
role of HIF-1 and mitochondrial ROS in Ang II–induced
VSMC migration.
DISCUSSION
Treating VSMCs with Ang II leads to altered HIF-1 proline
hydroxylation, decreased pVHL binding, reduced HIF-1
ubiquitination, and proteasomal degradation leading to in-
creased HIF-1 stabilization (Page et al., 2008). ROS genera-
tion plays a pivotal role in these Ang II–mediated effects on
the HIF-1 system. Our current work now identifies mito-
chondrial-derived ROS as essential intermediates leading to
the stabilization of HIF-1, the activation of HIF-1, increased
in HIF-1 target gene expression, and associated cellular ef-
fects, such as VSMC migration.
It is well accepted that the NADPH oxidase plays a pri-
mary role in VSMC biology. noxROS have been implicated
in various VSMC signaling mechanisms originating from
AT1 receptor activation after Ang II stimulation (Garrido
and Griendling, 2009). noxROS have been implicated in
increasing HIF-1 translation (Page et al., 2002; Lauzier et al.,
2007). Additionally, a recent study showed the involvement
of the NADPH oxidase in HIF-2 stabilization (Diebold et al.,
2010). Because Ang II–induced HIF-1 stability was ROS
dependent, our first studies pushed us to investigate the role
of the NADPH oxidase and noxROS in HIF-1 stabilization.
Under our conditions, the NADPH oxidase does not play a
major role in HIF-1 accumulation. This is shown here by
targeting p22phox by RNAi and using the specific NADPH
inhibitor, VAS2870. However, siRNA against other NADPH
oxidase subunits, including Nox1, Nox4 and p47phox, were
equally ineffective to block HIF-1 accumulation after Ang II
treatment. (D. A. Patten, E. L. Page´, and D. E. Richard,
unpublished observations). These unexpected results led us
Figure 7. mtROS inhibit VHL-HIF-1 binding. (A) Quiescent
VSMCs were pretreated with stigmatellin (1 M), myxothiazol (1
M), or VAS2870 (10 M) for 20 min and subsequently treated or
not with Ang II (100 nM) or CoCl2 for 4 h. Cytoplasmic extracts were
incubated with GST-HIF-1 coupled to Sepharose beads for 1 h.
Samples were then incubated in the presence of in vitro–translated
pVHL and resolved by SDS-PAGE (12%). Immunoblotting was
performed using anti-HA (pVHL) and anti-GST antibodies (A, top).
Western blots were quantified with the Odyssey Infrared Imaging
System using GST-HIF-1 as a loading control (A, bottom panel).
Results are expressed as a percentage of pVHL binding normalized
to GST-HIF-1 protein levels compared with untreated cells and are
an average  SEM of four independent experiments. **p  0.01 and
*p  0.05 compared with untreated VSMCs. (B) VSMCs were trans-
fected with a siRNA against p22phox or a control sequence. Quies-
cent VSMCs were treated or not with Ang II (100 nM) for 4 h.
VHL-capture assay was then performed as in A.
Figure 8. mtROS are essential for HIF-1– dependent activity. (A)
Quiescent VSMCs were pretreated with stigmatellin (1 M) or
myxothiazol (1 M) for 20 min and then treated or not with Ang
II (100 nM) for 4 h. Total RNA was extracted and resolved on
formaldehyde/agarose gels. Northern blotting was performed
using specific VEGF- and Glut-1–radiolabeled probes. An 18S
RNA probe was used as a control for gel loading. Northern blots
were quantified by phosphoimaging using total ribosomal 18S
RNA as a loading control (Bottom panels). Data expressed are an
average  SEM of four independent experiments. ***p  0.001
compared with untreated VSMCs. †p  0.05 compared with Ang
II–treated VSMCs. ‡Nonsignificant compared with Ang II–
treated VSMCs.
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to demonstrate here that mitochondrial/complex III–gener-
ated mtROS are indispensable for HIF-1 activation by Ang
II. It is important to note that the NADPH oxidase and the
mitochondria are not the only ROS-generating systems in
VSMCs (San Martin and Griendling, 2010). It is possible that
the activity of other oxidases and ROS generators may affect
HIF-1 activation at different levels. Continued studies in this
area will clarify the role of other oxidases and ROS genera-
tors on HIF-1 activation in nonhypoxic conditions.
Our previous work described that DPI, which blocks
ROS generation through its inhibitory effects on flavopro-
tein-containing enzymes, blocked HIF-1 accumulation
during Ang II treatment. We suggested this was mediated
through the inhibition of the NADPH oxidase. Not sur-
prisingly, it has been reported that DPI is not a specific
NADPH oxidase inhibitor (Hutchinson et al., 2007; Aldieri
et al., 2008). Moreover, DPI inhibits all flavin-containing
enzymes, including those found in the mitochondria (Li
and Trush, 1998). Here, our work shows that DPI does
indeed block mtROS generation in VSMCs during Ang II
treatment and indicates that DPI blocks HIF-1 stabiliza-
tion by Ang II.
Our results show that mtROS are essential for blocking
HIF-1 hydroxylation and pVHL binding during Ang II
treatment. It is well accepted that hydroxylation of proline
residues 564 and 402 (Pro402 and Pro564) of human HIF-1
regulates pVHL-mediated proteasomal degradation (Ivan et
al., 2001; Masson et al., 2001). Further studies indicated that
the modification of only one of these proline residues is
sufficient to stabilize HIF-1 (Chan et al., 2005). Our previous
work demonstrated that treating VSMCs with Ang II pri-
marily suppressed the hydroxylation of Pro402 (Page et al.,
2008). In agreement with these observations, here we show
that mtROS are responsible for decreasing Pro402 hydroxy-
lation while Pro564 hydroxylation is mostly unaffected.
Taken together, our results show that increased mtROS re-
sults in an inactivation of PHD.
H2O2 is known to be an important mediator of the effects
of Ang II on VSMC (Zafari et al., 1998). Our previous studies
demonstrated that H2O2 led to the inhibition of PHD activ-
ity, as measured by reduced pVHL/HIF-1 binding (Page et
al., 2008). This indicates that superoxide, produced in the
mitochondria, is transformed into H2O2, which effectively
inhibits PHD activity. This inhibition most probably occurs
due to the Fenton reaction and the oxidation of Fe2 to Fe3,
which decreases available ascorbate, leading to decreased
hydroxylation of HIF-1 on Pro402, impaired binding of
pVHL to HIF-1, and HIF-1 stabilization under normal
oxygen conditions. These results also suggest a crucial role
of superoxide dismutase (SOD) in HIF-1 activation by Ang
II. Preliminary evidence suggest that SOD activity is indeed
involved because diethylthiocarbamate (DETC), a SOD in-
hibitor, led to a significant inhibition of HIF-1 accumula-
tion under Ang II treatment in VSMCs (G. A. Robitaille and
D. E. Richard, unpublished observations). Further studies
are needed to clearly identify the role of different SOD
enzymes in HIF-1 activation. Given the importance of
mtROS in HIF-1 induction, mitochondrial SOD2 may be of
particular interest.
Because Ang II can activate both noxROS and mtROS in
VSMCs after Ang II treatment, our results indicate a speci-
ficity of mtROS in regulating HIF-1 stabilization. The rea-
son for this specificity for mtROS remains to be elucidated.
Theoretically, mtROS differ from noxROS by only the area in
which it is produced and the local expression of SOD. We
hypothesize that local mtROS/H2O2 gradients exist around
the mitochondria which is responsible for inhibition of PHD
activity and HIF-1 stabilization signaling.
Exactly how Ang II increases mtROS remains to be eluci-
dated. By using two ETC complex III inhibitors and a siRNA
against the Rieske Fe-S, our results indicate an essential role
of complex III. However, the exact sequence of events lead-
ing to complex III activation and mtROS generation after
AT1 receptor activation remains unclear. In contrast to our
findings, Kimura et al. (2005b) have proposed that in cardiac
tissue, mtROS are produced during Ang II treatment
through NADPH oxidase-derived ROS-induced ROS release
(RIRR). In other words, the initial burst of noxROS leads to
increased mtROS. Our results indicate that in VSMCs, RIRR
does not occur because inhibition of the NADPH oxidase
does not block Ang II–induced mtROS generation as mea-
sured by MitoSOX nor does it impede HIF-1 induction. It is
important to note that results from Kimura et al. were based
on data obtained using the classical NADPH oxidase inhib-
itor, apocynin. However, recent results now indicate that
apocynin is not a simple NADPH oxidase inhibitor in vas-
cular cells and can also act as an antioxidant (Heumuller et
Figure 9. mtROS are essential for Ang II–dependent VSMC mi-
gration. VSMCs were transfected with a siRNA against HIF-1 or a
control sequence (top) or left untransfected (bottom). Cells were
serum-starved 24 h after transfection. Quiescent VSMCs (5  105
cells/well) were placed in the upper level of a Boyden chamber and
allowed to migrate through a collagen-coated microporous mem-
brane for 4 h toward the lower chamber that contained 100 nM Ang
II in DMEM only (top) or in DMEM supplemented or not with
stigmatellin (1 M) or myxothiazol (1 M; bottom). Cells were then
fixed, stained, and counted as described in Materials and Methods.
Data expressed are an average  SEM of three independent exper-
iments performed in triplicate. ***p  0.001 compared with un-
treated () VSMCs.
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al., 2008). Additionally, it was shown that the expression of
a dominant negative form of Rac1 can suppress mtROS
generation by Ang II (Nozoe et al., 2008) Because Rac1 is
required for proper NADPH oxidase assembly, this sug-
gested that the NADPH oxidase is required for increasing
mtROS (Griendling et al., 2000). Although the role of Rac1 on
HIF-1 induction and activation has been described (Hirota
and Semenza, 2001), Rac1 also regulates other cellular pro-
cesses in VSMCs including cytoskeletal organization, gene
transcription, cell proliferation and membrane trafficking
through interactions with PI3K, p21-activated kinase (PAK),
Ras, and p70 S6 kinase (Chou and Blenis, 1996; Kaibuchi et
al., 1999; Liliental et al., 2000; Sun et al., 2000). Additionally,
Rac1 has been shown to regulate HIF-1 mRNA expression
through activation of the NF-B pathway in different cell
systems including VSMCs (Gorlach et al., 2003; Diebold et al.,
2008; Kim et al., 2008). Finally, previous studies have shown
that Rac1 does not affect mtROS generation in TNF-treated
endothelial cells (Deshpande et al., 2000). Therefore, the
effect of Rac1 on HIF-1 induction could potentially be attrib-
uted to any number of cellular processes not directly linked
to mtROS generation. Finally, a recent study shows that
inversely, mtROS can lead to NADPH oxidase activation
(Lee et al., 2006). Given these divergent studies and our
results, further investigation is needed to clearly delineate
the mechanisms by which mtROS generation is activated in
VSMCs after Ang II treatment.
HIF-1 regulation by Ang II occurs through three indepen-
dent mechanisms. Until now, we have been unable to deter-
mine which mechanism played a primordial role in HIF-1
induction and activation. Our work here partly defines the
relative contribution of the increased translation, transcrip-
tion, and stability of HIF-1 by Ang II. We can now specu-
late that increased HIF-1 stability is of primary importance
for HIF-1 regulation by Ang II. Also, because the inhibition
of the NADPH oxidase had little or no effect on HIF-1
accumulation, and we have previously demonstrated that
noxROS are important for increased HIF-1 translation by
Ang II; our results indicate that increased HIF-1 protein
translation is not essential for the prolonged accumulation of
HIF-1 levels under Ang II treatment (Page et al., 2002).
However, increased HIF-1 translation may be important
for the rapid accumulation of HIF-1 after Ang II receptor
activation.
Because mitochondrial oxidative damage is thought to
contribute in a number of human degenerative diseases,
the development of antioxidants that are targeted to the
mitochondria has gained significant interest. Generally,
mitochondrial antioxidants include an antioxidant moiety
(ubiquinone, tocopherol, nitroxide) and a covalently at-
tached lipophilic triphenylphosphonium cation that serves for
specific uptake by the mitochondria (Smith et al., 2008). MitoQ
and SkQ1 are two compounds that have been developed to
specifically suppress mtROS generation. These two com-
pounds have an added advantage over other mitochondrial-
targeted antioxidants because they can be regenerated by
accepting electrons from the respiratory chain. MitoQ has
been shown to inhibit HIF-1 accumulation during hypoxia
(Bell et al., 2007). However, recent evidence suggests that the
concentration window for MitoQ’s antioxidant properties is
very small before displaying prooxidant properties (An-
tonenko et al., 2008). Using a different antioxidant moiety
(plastoquinone), SkQ1 demonstrated more potent antioxi-
dant properties and a larger functional concentration win-
dow than MitoQ (Skulachev et al., 2009). Here, we success-
fully used SkQ1 to decrease mtROS generation during Ang
II treatment, which effectively inhibited HIF-1 accumula-
tion. Our studies therefore confirm the effectiveness of mi-
tochondrial antioxidants as inhibitors of HIF-1 activation
under nonhypoxic conditions and point to interesting ther-
apeutic leads. Our recent in vivo studies have demonstrated
a potential role for nonhypoxic HIF-1 induction in vascular
remodeling diseases (Lambert et al. 2010). Mitochondrial
antioxidants, such as SkQ1, will prove interesting tools for
further investigation in Ang II–mediated pathophysiological
effects which involve VSMC migration, such as vascular
remodeling.
Mitochondrial-derived ROS have gained substantial in-
terest in the regulation of HIF-1 induction and activation.
The hypoxic activation of HIF-1 has been shown by two
independent groups to be regulated by mtROS (Chandel
et al., 2000; Guzy et al., 2005). Additionally, a nonhypoxic
activator of HIF-1, thrombopoietin (TPO), has been shown
to control HIF-1 levels through the generation of mtROS
(Yoshida et al., 2008). Although the NADPH oxidase has
classically been shown as the primary ROS generator in
VSMCs and noxROS to be involved in different signaling
pathways, our study now identifies mtROS as an essential
intermediate for PHD inactivation, HIF-1 stabilization,
and HIF-1 activation when VSMCs are stimulated with
Ang II. Taken together, these studies suggest that mito-
chondrial ROS are a common intermediate signal trans-
ducer between hypoxic and nonhypoxic stimuli leading to
the activation of HIF-1.
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